Guideline on Setting Health Based Exposure Limits for Use in Risk Identification in the Manufacture of Different Medicinal Products in Shared Facilities
Sets out how to derive a health-based exposure limit — the permitted daily exposure — from toxicological and clinical data, for use in assessing cross-contamination risk where different medicinal products share a facility. Adopted 20 November 2014, effective 1 June 2015.
Always verify against the current published text before relying on it for a submission or inspection.
Scope & applicability
Shared manufacturing facilities, and the determination of whether dedicated facilities are required. It is the document that moved cleaning-validation limits away from arbitrary conventions such as one-thousandth of a dose or ten parts per million and onto a toxicological basis — which is also the basis on which an occupational exposure limit is derived, from the same underlying assessment.
Key requirements
- Derivation of a permitted daily exposure from a point of departure with justified adjustment factors
- Use of the PDE in cross-contamination risk assessment and in setting cleaning acceptance limits
- Assessment by a person with appropriate toxicological or pharmacological expertise, with the derivation documented
- Identification of compounds requiring dedicated or segregated facilities rather than shared ones
Implementation tips
- One toxicological assessment serves two obligations: the PDE that drives cleaning limits and the occupational exposure limit that drives containment. Commissioning them separately duplicates cost and can produce two numbers that disagree
- The derivation is the deliverable, not the number — a PDE without its point of departure and adjustment-factor rationale cannot be defended or updated when new data arrive
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
EMA/CHMP/CVMP/SWP/169430/2012: frequently asked questions
Quick answers to common questions about EMA/CHMP/CVMP/SWP/169430/2012.
What is EMA/CHMP/CVMP/SWP/169430/2012?
EMA/CHMP/CVMP/SWP/169430/2012 — Guideline on Setting Health Based Exposure Limits for Use in Risk Identification in the Manufacture of Different Medicinal Products in Shared Facilities — is a guideline issued by the European Medicines Agency (European Union). Sets out how to derive a health-based exposure limit — the permitted daily exposure — from toxicological and clinical data, for use in assessing cross-contamination risk where different medicinal products share a facility. Adopted 20 November 2014, effective 1 June 2015.
Who does EMA/CHMP/CVMP/SWP/169430/2012 apply to?
Shared manufacturing facilities, and the determination of whether dedicated facilities are required. It is the document that moved cleaning-validation limits away from arbitrary conventions such as one-thousandth of a dose or ten parts per million and onto a toxicological basis — which is also the basis on which an occupational exposure limit is derived, from the same underlying assessment.
What are the key requirements of EMA/CHMP/CVMP/SWP/169430/2012?
EMA/CHMP/CVMP/SWP/169430/2012 requires, among other things: Derivation of a permitted daily exposure from a point of departure with justified adjustment factors; Use of the PDE in cross-contamination risk assessment and in setting cleaning acceptance limits; Assessment by a person with appropriate toxicological or pharmacological expertise, with the derivation documented; Identification of compounds requiring dedicated or segregated facilities rather than shared ones.
When was EMA/CHMP/CVMP/SWP/169430/2012 last updated?
The current version of EMA/CHMP/CVMP/SWP/169430/2012 dates from June 2015.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.